DKK356.70
1.64% yesterday
Copenhagen, Aug 27, 04:59 pm CET
ISIN
DK0062498333
Symbol
NOVO B

Novo Nordisk Stock price

DKK356.70
-94.45 20.94% 1M
-285.10 44.42% 6M
-267.50 42.85% YTD
-547.40 60.55% 1Y
-45.30 11.27% 3Y
+147.63 70.61% 5Y
+171.65 92.76% 10Y
+325.35 1,037.80% 20Y
Copenhagen, Closing price Wed, Aug 27 2025
+5.75 1.64%
ISIN
DK0062498333
Symbol
NOVO B
Industry

Key metrics

Basic
Market capitalization
DKK1.6t
Enterprise Value
DKK1.7t
Net debt
DKK80.3b
Cash
DKK18.9b
Shares outstanding
4.4b
Valuation (TTM | estimate)
P/E
14.1 | 13.9
P/S
5.2 | 5.1
EV/Sales
5.5 | 5.4
EV/FCF
27.8
P/B
9.7
Dividends
DPS
DKK11.40
Yield 1Y | 5Y
3.3% | 1.6%
Growth 1Y | 5Y
21.3% | 22.3%
Payout 1Y | 3Y
50.4% | 50.5%
Increased
18 Years
Financials (TTM | estimate)
Revenue
DKK311.9b | DKK319.5b
EBITDA
DKK158.8b | DKK169.9b
EBIT
DKK142.8b | DKK153.8b
Net Income
DKK111.1b | DKK112.0b
Free Cash Flow
DKK61.6b
Growth (TTM | estimate)
Revenue
20.9% | 10.0%
EBITDA
18.1% | 19.4%
EBIT
21.9% | 10.7%
Net Income
23.5% | 10.9%
Free Cash Flow
-6.7%
Margin (TTM | estimate)
Gross
84.0%
EBITDA
50.9% | 53.2%
EBIT
45.8%
Net
35.6% | 35.1%
Free Cash Flow
19.8%
Financial Health
Equity Ratio
30.8%
Return on Equity
70.4%
ROCE
52.0%
ROIC
42.1%
Debt/Equity
0.6
More
EPS
DKK25.0
FCF per Share
DKK13.9
Short interest
-
Employees
77k
Rev per Employee
DKK3.8m
Show more

Is Novo Nordisk a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Novo Nordisk Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Novo Nordisk forecast:

17x Buy
55%
12x Hold
39%
2x Sell
6%

Analyst Opinions

31 Analysts have issued a Novo Nordisk forecast:

Buy
55%
Hold
39%
Sell
6%

Financial data from Novo Nordisk

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
311,938 311,938
21% 21%
100%
- Direct Costs 50,068 50,068
25% 25%
16%
261,870 261,870
20% 20%
84%
- Selling and Administrative Expenses 71,834 71,834
14% 14%
23%
- Research and Development Expense 45,288 45,288
20% 20%
15%
158,810 158,810
18% 18%
51%
- Depreciation and Amortization 16,011 16,011
7% 7%
5%
EBIT (Operating Income) EBIT 142,799 142,799
22% 22%
46%
Net Profit 111,068 111,068
24% 24%
36%

In millions DKK.

Don't miss a Thing! We will send you all news about Novo Nordisk directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novo Nordisk Stock News

AD HOC NEWS
10 days ago
Eine weitere US-Zulassung für den Gewichtssenker Wegovy von Novo Nordisk DK0062498333 dürfte am Montag den Bodenbildungsversuch der Aktien des dänischen Pharmakonzerns vorantreiben.
AD HOC NEWS
10 days ago
KOPENHAGEN - Eine weitere US-Zulassung für den Gewichtssenker Wegovy von Novo Nordisk DK0062498333 dürfte am Montag den Bodenbildungsversuch der Aktien des dänischen Pharmakonzerns vorantreiben.
AD HOC NEWS
22 days ago
Ein enttäuschendes zweites Quartal hat den Anlegern von Novo Nordisk DK0062498333 zur Wochenmitte nochmals kräftige Verluste eingebrockt.
More Novo Nordisk News

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Head office Denmark
CEO Lars Jørgensen
Employees 76,826
Founded 1931
Website www.novonordisk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today